SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Epigral to raise funds up to Rs 400 crore

04 Aug 2025 Evaluate

Epigral has received approval to raise funds up to Rs 400 crore by way of issuance of non-convertible debentures (NCDs), bonds and/or other debt securities etc. through permissible mode within the borrowing limits of the company, in one or more tranches / series. The board of directors of the company in their meeting held on August 2, 2025, have approved the same.

Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.

Epigral Share Price

1327.55 -44.20 (-3.22%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 4035.90
Tata Chemicals 782.10
SRF 2780.75
Pidilite Inds. 1476.15
Deepak Nitrite 1875.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×